John W. Childs Purchases 29,000 Shares of Biohaven Ltd. (NYSE:BHVN) Stock

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs acquired 29,000 shares of Biohaven stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares in the company, valued at $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Biohaven Stock Up 4.4 %

BHVN opened at $37.35 on Thursday. The firm has a 50-day simple moving average of $44.71 and a two-hundred day simple moving average of $42.02. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The company has a market capitalization of $3.78 billion, a PE ratio of -3.99 and a beta of 1.24.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, sell-side analysts expect that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

BHVN has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price objective on Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Jefferies Financial Group began coverage on Biohaven in a research note on Monday, September 16th. They issued a “buy” rating and a $57.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target (up previously from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Sanford C. Bernstein increased their price target on Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 24th. Finally, Leerink Partners increased their price target on Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Biohaven presently has an average rating of “Buy” and an average target price of $63.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SpiderRock Advisors LLC bought a new position in shares of Biohaven in the 3rd quarter valued at about $620,000. Citigroup Inc. lifted its stake in Biohaven by 125.8% in the third quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock worth $5,992,000 after purchasing an additional 66,801 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Biohaven in the third quarter worth about $1,339,000. XTX Topco Ltd lifted its stake in Biohaven by 278.5% in the third quarter. XTX Topco Ltd now owns 32,510 shares of the company’s stock worth $1,625,000 after purchasing an additional 23,921 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Biohaven by 234.5% in the second quarter. Principal Financial Group Inc. now owns 79,048 shares of the company’s stock worth $2,744,000 after purchasing an additional 55,415 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.